MARK SEGAL, MD
Medical Oncology Physician in COLUMBUS, Ohio. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
MARK SEGAL, MD reported a CMS MIPS final score of 75/100 — below the 83.1 national average — and filed 919 Medicare Part D claims in 2023.
- 75/100
- MIPS score · -8 vs avg
- 919
- Part D claims, 2023
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
MARK SEGAL, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
75 15th percentile higher than 15% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
MARK SEGAL, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about MARK SEGAL, MD?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Ohio
How Medical Oncology Physician compares to other specialties among Ohio providers
Medical Oncology Physician share within Ohio
Medical Oncology Physician is one of the more visible NUCC categories in Ohio
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
MARK SEGAL, MD's 2023 MIPS final score plotted against the Medical Oncology Physician national average
- MIPS Final Score
- 75/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Medical Oncology Physician) — 75/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Specialty volume Medical Oncology Physician US NPIs
75/100 MIPS final score — 8.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Medical Oncology Physician.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MARK SEGAL, MD appears in the CMS NPPES registry as a Medical Oncology Physician provider holding MD credentials at 3100 PLAZA PROPERTIES BLVD, COLUMBUS, OH, 43219, with a listed phone of (614) 383-6000. NPI 1093715385 was issued on 07/28/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what SEGAL most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 919 prescription claims written by this provider, covering 196 Medicare beneficiaries and totaling roughly $1.4 million in drug spend, with an opioid prescribing rate of 25.5%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 75/100 for the 2023 performance year, compared with the national average of 83.1.
Medical Oncology Physician is a narrow specialty nationwide, with 3,792 enrolled providers across 53 states and an average of 689 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1093715385 |
|---|---|
| Specialty | Medical Oncology Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 07/28/2005 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MARK SEGAL, MD's current license status, disciplinary history, and board certifications with the State Medical Board of Ohio in Ohio before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARK SEGAL, MD. Source: openpaymentsdata.cms.gov.
Total received
$3.7K
Largest payer
Novartis Pharmaceuticals Corporation
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — Ohio OMB 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~48K Ohio medical licensees in 2023 — they are NOT specific to MARK SEGAL, MD. To verify MARK SEGAL, MD's current license status, search the OMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
OMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Ohio disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,286
- Total Day Supply
- 32,824
- Generic Drug Cost
- $83K
- Opioid Claims
- 234 (25.5% rate)
- Antibiotic Claims
- 30
Patient Demographics
- Average Patient Age
- 73.5 years
- Avg HCC Risk Score
- 1.98
- Gender Split
- 65% female / 35% male
- Age Distribution
- <65: 22, 65-74: 80, 75-84: 67, 85+: 27
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What MARK SEGAL, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Letrozole
Letrozole
102 claims
- Oxycodone Hcl
Oxycodone Hcl
79 claims
- Hydroxyurea
Hydroxyurea
69 claims
- Oxycodone-Acetamin…
Oxycodone-Acetaminophen
60 claims
- Hydrocodone-Acetam…
Hydrocodone-Acetaminophen
50 claims
- Prochlorperazine M…
Prochlorperazine Maleate
42 claims
- Prednisone 38
Prednisone
38 claims
- Acyclovir 24
Acyclovir
24 claims
| Drug | Claims |
|---|---|
| Letrozole | 102 |
| Oxycodone Hcl | 79 |
| Hydroxyurea | 69 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 60 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 50 |
| Prochlorperazine Maleate | 42 |
| Prednisone | 38 |
| Acyclovir | 24 |
| Dexamethasone | 23 |
| Revlimid Lenalidomide | 23 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Medical Oncology Physician Overview
How MARK SEGAL, MD fits within the Medical Oncology Physician landscape nationally.
MARK SEGAL, MD's 919 claims are above the specialty average of 689.
Nearby Medical Oncology Physician Providers in Ohio
Other clinicians with the same primary specialty enrolled in Ohio, drawn from the same CMS NPPES roster as SEGAL.
Compare Medical Oncology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Ohio
Frequently Asked Questions
What is MARK SEGAL, MD's specialty? ▼
How much does MARK SEGAL, MD prescribe under Medicare Part D? ▼
What is MARK SEGAL, MD's Medicare quality score? ▼
Where is MARK SEGAL, MD located? ▼
What is MARK SEGAL, MD's NPI number? ▼
Does MARK SEGAL, MD prescribe opioids? ▼
How many Medical Oncology Physician providers are there in the US? ▼
What drugs does MARK SEGAL, MD prescribe most often? ▼
Does MARK SEGAL, MD accept Medicare? ▼
How can I verify MARK SEGAL, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology